Stalling the Course of Neurodegenerative Diseases: Could Cyanobacteria Constitute a New Approach toward Therapy?

• Type: Another Publication in an International Scientific Journal
• Date: 2023

Authors

Ramos, V (Author) Other; Reis, M (Author) Other; Ferreira, L (Author) Other; Silva, AM (Author) Other; Ferraz, R (Author) Other; Vieira, M (Author) Other; Vitor Vasconcelos (Author) FCUP; Martins, R (Author) Other

Journal

Title: Biomolecules

Vol. 13

ISSN: 2218-273X

Publisher: MDPI

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Other information

Authenticus ID: P-00Z-9PM

DOI: 10.3390/biom13101444

Abstract (EN): Neurodegenerative diseases (NDs) are characterized by progressive and irreversible neuronal loss, accompanied by a range of pathological pathways, including aberrant protein aggregation, altered energy metabolism, excitotoxicity, inflammation, and oxidative stress. Some of the most common NDs include Alzheimer's Disease (AD), Parkinson's Disease (PD), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and Huntington's Disease (HD). There are currently no available cures; there are only therapeutic approaches that ameliorate the progression of symptoms, which makes the search for new drugs and therapeutic targets a constant battle. Cyanobacteria are ancient prokaryotic oxygenic phototrophs whose long evolutionary history has resulted in the production of a plethora of biomedically relevant compounds with anti-inflammatory, antioxidant, immunomodulatory, and neuroprotective properties, that can be valuable in this field. This review summarizes the major NDs and their pathophysiology, with a focus on the anti-neurodegenerative properties of cyanobacterial compounds and their main effects.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 34